Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
NEEDHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company’s immunotherapy portfolio and provided updates on multiple upcoming milestones.
Related news for (CADL)
- Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
- 24/7 Market News Snapshot 09 July, 2025 – Candel Therapeutics, Inc. Common Stock (NASDAQ:CADL)
- Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
- Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors